1.Expression and significance of FoxP3 in non-keratinizing squamous cell carcinoma of nasopharynx *
Chongqing Medicine 2013;(27):3272-3274
Objective To investigate the expression of FoxP3 in nasopharyngeal non-keratinizing squamous cell carcinoma and the significance of regulationary T (Treg) cell in the occurrence and development of nasopharyngeal carcinoma .Methods The im-munohistochemistry staining method(SP) was used to detect the expression of FoxP3 in 57 cases of nasopharyngeal non-keratiniz-ing squamous cell carcinoma and 22 cases of nasopharyngeal mucosa with chronic inflammation ,and the expression of CD8 in naso-pharyngeal carcinoma .Results The number of Treg cell with positive FoxP3 in the nasopharyngeal carcinoma group was 105 .05 ± 52 .22 ,which was significantly higher than 6 .35 ± 6 .06 in the nasopharyngeal mucosa with chronic inflammation ,the difference be-tween them showed statistical significance(P<0 .05) .The number of T cells with positive FoxP3 was relevant to gender and the differentiation degree of carcinoma(P<0 .05) .Conclusion The proliferation of Treg cells with positive FoxP3 can inhibit the anti-tumor immunologic function of the patients with nasopharyngeal non-keratinizing squamous cell carcinoma and provide the favor-able environment for the immunologic escape of tumor cells .
3.Preparation of Metoprolol Succinate Sustained-Release Tablet and Its Content Determination
Herald of Medicine 2016;35(8):870-874
Objective To establish a method of preparing metoprolol succinate sustained-release tablet and its content determination. Methods The formulation was optimized through the orthogonal design test by using release rate of the drug as an indicator.The different batches of metoprolol succinate sustained-release tablets were determined by HPLC. Results The tablets could release drug steadily and slowly as designed,which was similar to imported tablets. The linear range of metoprolol succinate was 10-70 μg?mL-1( r=0.999 8) . Conclusion The releasing rate of metoprolol succinate sustained-release tablet prepared in optimum condition can meet the requirement. This preparation technology is simple, the assay method is rapid, sensitive and reproducible.
5.MicroRNA and Tumor
Journal of International Oncology 2006;0(10):-
MicroRNAs(miRNAs) are small mm-coding RNA molecules that post-transcriptionul-ly regulate gene expression. Advanced studies show that miRNA are involved in cancer. Even some scientists regard miRNAs as oncogenes or tumor associated genes. This review tries to have a brief introduction on the progress in the relationship between miRNAs and tumor's formation,development,diagnosis,therapy and prognosis in humans.
6.Progress in molecularly targeted anti-tumor drugs derived from natural products or their derivatives
Acta Pharmaceutica Sinica 2020;55(11):2491-2500
Conventional chemotherapy drugs, molecularly targeted drugs, and immune checkpoint inhibitors are the major constituents of anti-tumor drugs in clinical settings at present. Molecularly targeted drugs specifically target the key proteins, genes, or signal transduction pathways in tumor cells which are essential for initiation and development of tumor, resulting in selective activity to induce cell death or growth inhibition. Molecularly targeted drugs have emerged as the mainstream in the research and development of anti-tumor drugs due to its high selectivity and low toxicity. Natural products refer to the chemical constituents or metabolites originated animals, plants, or microorganisms, which have been recognized as one of the important sources of drug discovery with abundant resources and diversified structures. At present, a number of molecularly targeted anti-tumor drugs derived from natural products or their derivatives have been approved for cancer therapy or in clinical trials. This review will summarize the molecularly targeted anti-tumor drugs derived from natural products or their derivatives according to their different cellular targets, and also outline the molecular mechanism, progress, and perspectives of these drugs.
7.Significance of anticentromere antibody in primary biliary cirrhosis
Xu-Hua SHI ; Fengchun ZHANG ; Xuan ZHANG ;
Chinese Journal of Rheumatology 2003;0(08):-
Objective To investigate the significance of anticentromere antibody(ACA)in patients with primary biliary cirrhosis(PBC).Method ACA was detected using indirect immunofluorescence(IIF)in 99 patients with PBC,and the difference was compared between patients with and without ACA.Results Fifty-three patients(53.5%)had ACA in serum.The average age of onset was elder in patients with ACA than in patients without ACA[(52.6?1.5)vs(46.2?2.0),P=0.012].There was no significant difference in sex ratio between the two groups.Incidence of gastrointestinal bleeding was higher in patients with than without ACA (13.2% vs 0,P=0.014).Difference was not significant in symptoms such as fatigue,pruritus,icterus,etc. Though it didn't reach statistically significant,the incidence of esophageal varices was higher in patients with ACA than without ACA(45.8% vs 10.0% respectively,P=0.061).There was no significant difference in diam- eter of portal vein,splenomegaly,ascites.Biochemically only serum total protein reached statistical significance between the two groups[(73.3+1.1)g/L vs(78.1+l.7)g/L respectively,P=0.017].Patients with ACA had low- er serum IgG than ACA negative patients[(15.1?0.6)g/L vs(18.4?1.0)g/L respectively,P=0.006].Nuclear envelope pattern(NE),one of the patterns of ANA,was rare in ACA positive group than ACA negative group (16.7% vs 50.0% respectively,P=0.002).Conclusion The prevalence of ACA is high in patients with PBC. Patients with ACA have high risk of oesophageal varices and gastrointestinal bleeding.Nuclear envelope pat- tern of ANA is rare in patients with ACA.
9.BML-111, the analogue of lipoxin, inhibits Hela cell proliferation
Hua HAO ; Fen XU ; Liqing WU ; Xinxin ZHANG ; Hua DAI
The Journal of Practical Medicine 2014;(13):2045-2047
Objective To investigate the effect of BML-111 (the analogue of lipoxin) on uterine Hela cell (cervix cancer cell line) proliferation and the underlying mechanism. Methods Hela cells were stimulated by 50, 100, 200 and 400 μg/L BML-111, respectively, and cell viability was determined by MTT assay. Hela cells were divided into three groups:the control group (no treatment), the BML-111(200μg/L) group and the BML-111(200μg/L)plus Boc-2 (10μmol/L)group. Expression and location of P53 protein were detected by immunofluorescence. Expressions of NF-κB p65,P53 and CyclinD1 protein were detected by Western blotting. Results BML-111 (100, 200 and 400 μg/L) could effectively inhibit Hela cell viability compared with the control group (P < 0.05). P53 expression was shown decreased in both the nucleus and the cytoplasm without any change of P53 location , however, Boc-2 could reverse this effect. BML-111 could effectively inhibit P53 and CyclinD1 expression via NF-κB pathway and the effects could also be inhibited by Boc-2. Conclusions BML-111 can effectively inhibit Hela cell proliferation via FPR2 and NF-κB pathway.
10.The correlations between the different pathological types gastritis and the expressions of AQP3 and AQP4
Peng YANG ; Hua XU ; Hua ZHANG ; Huigang CHE ; Jianxiang WANG
The Journal of Practical Medicine 2015;31(15):2471-2474
Objective To explore the correlations of expressions of gastric mucosa water channel aquaporin AQP3 and AQP4 and different gastritis types. Methods The gastric mucosa was mounted under gastroscope. The types of gastric mucosa pathology and activity were tested by the common pathohistology. The expressions of AQP3 and AQP4 were determined by immunohistology. Results The expressions of AQP3 and AQP4 of chronic superficial gastritis were significantly higher than those in the non-gastritis group and chronic atrophic gastritis group (P < 0.01), especially in the activity period of chronic superficial gastritis. The expressions of AQP3 and AQP4 of chronic atrophic gastritis group were reduced when compared to those in the non-gastritis group, in spite of no statistical differences between them. While compared to the non-gastritis group , the expression of AQP3 of chronic atrophic gastritis group during the active stage was remarkably decreased (P < 0.05). Conclusion The expressions of AQP3 and AQP4 of gastric mucosa in chronic gastritis in various pathological types are different. AQP3 and AQP4 may be the targeted point , which could be used for the differential diagnosis and treatment of chronic gastritis of different pathological types.